Demonstrate continued long term safety of Zorblisa assessed via monitoring of local tolerability at the application sites, occurrence of adverse events and physical examinations. Results will be summarized

Changes in Body Surface Area (BSA) of lesional skin and wound burden using BSAI

150

All

1 Month and older (Child, Adult, Senior)

NCT02670330

SD-0062014-005679-96

May 2015

May 2019

May 2019

February 1, 2016

April 26, 2017

Phoenix Children's HospitalPhoenix, Arizona, United States

Stanford University-Dept of DermatologyRedwood City, California, United States

University of Colorado School of MedicineAurora, Colorado, United States